Viral dynamics in primary HIV-1 infection

Aids

14, 2283-2291

DOI: 10.1097/00002030-200010200-00009

Citation Report

#	Article	IF	Citations
1	Evidence for a diagnostic window in fourth generation assays for HIV. Journal of Clinical Virology, 2001, 23, 113-116.	1.6	36
2	Initiation of Therapy during Primary HIV Type 1 Infection Results in a Continuous Decay of Proviral DNA and a Highly Restricted Viral Evolution. AIDS Research and Human Retroviruses, 2001, 17, 409-416.	0.5	25
3	HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. Aids, 2001, 15, 837-845.	1.0	144
4	Comment on â€œDynamics of HIV Infection: A Cellular Automata Approachâ€• Physical Review Letters, 2002, 89, 219805.	2.9	13
5	SIVmac pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. Aids, 2002, 16, 1489-1496.	1.0	215
6	Use of laboratory tests and clinical symptoms for identification of primary HIV infection. Aids, 2002, 16, 1119-1129.	1.0	236
7	Treatment of primary HIV. Current Infectious Disease Reports, 2002, 4, 81-87.	1.3	9
8	Longitudinal follow up of SIVmac pathogenesis in rhesus macaques of Chinese origin: emergence of B cell lymphoma. Journal of Medical Primatology, 2002, 31, 154-163.	0.3	20
9	Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo. Virology, 2003, 306, 100-108.	1.1	19
10	Glancing behind virus load variation in HIV-1 infection. Trends in Microbiology, 2003, 11, 499-504.	3.5	55
11	Follow-up of Antiretroviral Treatment in Liver Transplant Recipients with Primary and Chronic HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2003, 19, 13-19.	0.5	13
12	Pediatric Viral Human Immunodeficiency Virus Type 1 RNA Levels, Timing of Infection, and Disease Progression in African HIV-1-Infected Children. Pediatrics, 2003, 112, e289-e289.	1.0	65
13	AIDS Vaccines That Allow HIV-1 to Infect and Escape Immunologic Control. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 214-220.	0.9	18
14	Dynamics of HIV viremia and antibody seroconversion in plasma donors. Aids, 2003, 17, 1871-1879.	1.0	1,107
15	Rapid Clearance of Virus after Acute HIVâ€1 Infection: Correlates of Risk of AIDS. Journal of Infectious Diseases, 2004, 189, 1793-1801.	1.9	39
16	Brief but Efficient: Acute HIV Infection and the Sexual Transmission of HIV. Journal of Infectious Diseases, 2004, 189, 1785-1792.	1.9	594
17	Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?. Aids, 2004, 18, 709-718.	1.0	89
18	Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. Journal of General Virology, 2004, 85, 2407-2419.	1.3	59

#	Article	IF	Citations
19	Multiple V1/V2 env Variants Are Frequently Present during Primary Infection with Human Immunodeficiency Virus Type 1. Journal of Virology, 2004, 78, 11208-11218.	1.5	116
20	ErupciÃ³n cutÃ¡nea en la primoinfecciÃ³n por el virus de la inmunodeficiencia humana. Actas Dermo-sifiliogrÃ¡ficas, 2004, 95, 385-389.	0.2	1
21	Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. Aids, 2005, 19, 85-90.	1.0	152
22	Spatial models of virus-immune dynamics. Journal of Theoretical Biology, 2005, 233, 221-236.	0.8	104
23	Detection of Antibody-Dependent Complement-Mediated Inactivation of both Autologous and Heterologous Virus in Primary Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2005, 79, 2823-2830.	1.5	87
24	The Cost-Effectiveness of Expanded Testing for Primary HIV Infection. Annals of Family Medicine, 2005, 3, 391-399.	0.9	26
25	Competition of pathogen strains leading to infection with variable infectivity and the effect of treatment. Mathematical Biosciences, 2005, 197, 153-172.	0.9	3
26	Early induction of leukemia inhibitor factor (LIF) in acute HIV-1 infection. Aids, 2006, 20, 11-19.	1.0	10
27	Viral dynamics after starting first-line HAART in HIV-1-infected children. Aids, 2006, 20, 517-523.	1.0	4
28	Approaching "HIV elimination": Interventions for acute HIV infection. Current HIV/AIDS Reports, 2006, 3, 160-168.	1.1	27
29	Multiple Polyexponentials and Quasipolynomials as Empirical Nonlinear Regression Models: A Case Study with HIV Viral Load Data. Journal of Biopharmaceutical Statistics, 2006, 16, 165-179.	0.4	2
30	Optimal Timing and Duration of Induction Therapy for HIV-1 Infection. PLoS Computational Biology, 2007, 3, e133.	1.5	9
31	The Relation Between Symptoms, Viral Load, and Viral Load Set Point in Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 445-448.	0.9	70
32	How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?. Aids, 2007, 21, 1625-1629.	1.0	73
33	Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. Aids, 2007, 21, 565-574.	1.0	63
34	Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. Aids, 2007, 21, 2237-2242.	1.0	86
35	Diagnosis and Management of Acute HIV Infection. Infectious Disease Clinics of North America, 2007, 21, 19-48.	1.9	95
36	Probability of resistance evolution for exponentially growing virus in the host. Journal of Theoretical Biology, 2007, 246, 323-331.	0.8	8

#	Article	IF	Citations
37	Probability of HIV Transmission During Acute Infection in Rakai, Uganda. AIDS and Behavior, 2008, 12, 677-684.	1.4	102
38	Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing. Journal of Virology, 2008, 82, 3952-3970.	1.5	540
39	Risk Factors for Delayed Initiation of Medical Care After Diagnosis of Human Immunodeficiency Virus. Archives of Internal Medicine, 2008, 168, 1181.	4.3	141
40	Acute Maternal HIV Infection during Pregnancy and Breastâ€Feeding: Substantial Risk to Infants. Journal of Infectious Diseases, 2009, 200, 667-669.	1.9	32
41	Modeling sequence evolution in acute HIV-1 infection. Journal of Theoretical Biology, 2009, 261, 341-360.	0.8	162
42	Kinetics of plasma cytokines and chemokines during primary HIVâ€1 infection and after analytical treatment interruption. HIV Medicine, 2009, 10, 94-102.	1.0	32
43	Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection. Journal of Theoretical Biology, 2009, 259, 751-759.	0.8	80
44	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1273-1289.	4.2	684
45	HIV RNA levels in transmission sources only weakly predict plasma viral load in recipients. Aids, 2010, 24, 1607-1608.	1.0	26
46	Modeling the dynamics of biomarkers during primary HIV infection taking into account the uncertainty of infection date. Annals of Applied Statistics, 2010, 4, .	0.5	6
47	The incidence of HIV among women recruited during late pregnancy and followed up for six years after childbirth in Zimbabwe. BMC Public Health, 2010, 10, 668.	1.2	24
48	Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection. Journal of Virology, 2010, 84, 2395-2407.	1.5	142
49	Effectiveness of a 'hunter' virus in controlling human immunodeficiency virus type 1 infection. Journal of General Virology, 2010, 91, 2513-2523.	1.3	1
50	Low Prevalence Rate of Indeterminate Serological Human Immunodeficiency Virus Results among Pregnant Women from Burkina Faso, West Africa. Journal of Clinical Microbiology, 2010, 48, 1333-1336.	1.8	9
51	Acute HIV Infection: Diagnosis and Management in the Emergency Department. Emergency Medicine Clinics of North America, 2010, 28, 381-392.	0.5	10
52	Acute HIV Infection Induces Mucosal Infiltration With CD4+ and CD8+ T Cells, Epithelial Apoptosis, and a Mucosal Barrier Defect. Gastroenterology, 2010, 139, 1289-1300.e2.	0.6	78
53	The acute HIV infection: implications for intervention, prevention and development of an effective AIDS vaccine. Current Opinion in Virology, 2011, 1, 204-210.	2.6	7
54	Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?. Clinical Infectious Diseases, 2011, 53, 1265-1270.	2.9	94

#	Article	IF	Citations
55	HIV testing: the cornerstone of HIV prevention efforts in the USA. Future Virology, 2011, 6, 1299-1317.	0.9	5
56	The costâ€effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. Transfusion, 2011, 51, 421-429.	0.8	33
57	Broad neutralizing antibody response and genetic variation in HIV-1 env genes in Koreans with primary HIV-1 infections. Archives of Virology, 2011, 156, 465-472.	0.9	1
58	Is the recall of men who have sex with men (MSM) diagnosed as having bacterial sexually transmitted infections (STIs) for re-screening a feasible and effective strategy?. Sexually Transmitted Infections, 2011, 87, 577-582.	0.8	22
59	Association of recent HIV infection and in-utero HIV-1 transmission. Aids, 2011, 25, 1357-1364.	1.0	23
60	Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. Journal of Infectious Diseases, 2011, 204, 753-760.	1.9	125
61	HIV Transmission. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006965-a006965.	2.9	257
62	A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns. BMC Systems Biology, 2013, 7, 11.	3.0	20
63	Simple Estimation of Incident HIV Infection Rates in Notification Cohorts Based on Window Periods of Algorithms for Evaluation of Line-Immunoassay Result Patterns. PLoS ONE, 2013, 8, e71662.	1.1	7
64	HIV and other Retroviral Infections of the Nervous System. , 2014, , 885-909.		0
65	Human Immunodeficiency Viruses Types 1 and 2. , 2014, , 1001-1062.		0
66	Update on antiretroviral treatment during primary HIV infection. Expert Review of Anti-Infective Therapy, 2014, 12, 793-807.	2.0	23
67	Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary Perspective. Science, 2014, 343, 1243727.	6.0	215
68	Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology, 2014, 83, 1592-1600.	1.5	70
69	Cost-effectiveness of a repeat HIV test in pregnancy in India. BMJ Open, 2015, 5, e006718-e006718.	0.8	16
70	Decreasing Proportion of Recent Infections among Newly Diagnosed HIV-1 Cases in Switzerland, 2008 to 2013 Based on Line-Immunoassay-Based Algorithms. PLoS ONE, 2015, 10, e0131828.	1.1	2
71	Clinical Applications of Quantitative Real-Time PCR in Virology. Methods in Microbiology, 2015, 42, 161-197.	0.4	6
72	Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. New England Journal of Medicine, 2016, 374, 2120-2130.	13.9	229

#	Article	IF	Citations
73	Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis. Journal of NeuroImmune Pharmacology, 2016, 11, 332-347.	2.1	4
74	Lessons from acute HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 555-560.	1.5	47
75	On the modeling and analysis of the biological regulatory network of NF-$${kappa }$$B activation in HIV-1 infection. Complex Adaptive Systems Modeling, 2016, 4, .	1.6	11
76	Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Infectious Diseases, 2016, 48, 93-98.	1.4	7
77	Differences in acute retroviral syndrome by HIV-1 subtype in a multicentre cohort study in Africa. Aids, 2017, 31, 2541-2546.	1.0	13
78	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. Journal of the International AIDS Society, 2017, 20, 21579.	1.2	107
79	Role of Innate Genes in HIV Replication. Current Topics in Microbiology and Immunology, 2017, 419, 69-111.	0.7	6
80	A mathematical model for CTL effect on a latently infected cell inclusive HIV dynamics and treatment. AIP Conference Proceedings, 2017, , .	0.3	7
81	Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa. PLoS ONE, 2018, 13, e0192785.	1.1	4
82	Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection. EBioMedicine, 2019, 43, 307-316.	2.7	61
83	Point-of-care HIV RNA testing and immediate antiretroviral therapy initiation in young adults seeking out-patient care in Kenya. Aids, 2019, 33, 923-926.	1.0	5
84	Pilot testing of an online training module about screening for acute HIV infection in adult patients seeking urgent healthcare. International Health, 2019, 11, 93-100.	0.8	7
85	Human Immunodeficiency Virus: A Brief Review. , 2020, , 183-200.		0
86	A Stronger Innate Immune Response During Hyperacute Human Immunodeficiency Virus Type 1 (HIV-1) Infection Is Associated With Acute Retroviral Syndrome. Clinical Infectious Diseases, 2021, 73, 832-841.	2.9	5
87	Sequential Broadening of CTL Responses in Early HIV-1 Infection Is Associated with Viral Escape. PLoS ONE, 2007, 2, e225.	1.1	68
89	HIV Disease Dynamics and Markers of Inflammation and CNS Injury During Primary HIV Infection and Their Relationship to Cognitive Performance. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 183-190.	0.9	6
90	HIV-1 Sequence Diversity as a Window Into HIV-1 Biology. , 2008, , 289-297.		0
91	Staged HIV transmission and treatment in a dynamic model with long-term partnerships. Journal of Mathematical Biology, 2023, 86, .	0.8	0

#	Article	IF	Citations